Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

China Biopharmaceutical and Pharmaceutical Regulatory Framework Reforms

The China Food and Drug Administration has noted a number of reforms to biopharmaceutical and pharmaceutical policy frameworks, aiming to encourage development, approval, and manufacture of required therapies.

Shanghai-based legal experts Katherine Wang and Xiaoyi Liu of Ropes & Gray explain key elements of these new regulations and implications on Western companies.

Download this free whitepaper to find an overview of the Chinese Food and Drug Administrations’s new programmes, answering questions such as what opportunities will be presented to Western contract manufacturers, what does the new classification system for new drugs mean for Western companies wishing to introduce new drugs to the Chinese market, and what opportunities are available for Western companies under the fast-track approval pathway?

China Biopharmaceutical and Pharmaceutical Regulatory Framework Reforms

For Free, instant access, click below.

Download Whitepaper

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.

Thank You

Your white paper is now downloading... Click here if the download does not begin.

Go Top